---
title: "Eledon Pharmaceuticals, Inc. (ELDN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ELDN.US.md"
symbol: "ELDN.US"
name: "Eledon Pharmaceuticals, Inc."
industry: "Biotechnology"
datetime: "2026-05-21T19:26:45.586Z"
locales:
  - [en](https://longbridge.com/en/quote/ELDN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ELDN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ELDN.US.md)
---

# Eledon Pharmaceuticals, Inc. (ELDN.US)

## Company Overview

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [eledon.com](https://eledon.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.73 | 330 | 13.62 | 10.67 | 10.39 |
| PB | 2.90 | 247 | 2.06 | 1.66 | 1.41 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.87 |
| Highest Target | 12.00 |
| Lowest Target | 4.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ELDN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ELDN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ELDN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ELDN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**